Fundraising Fox
Altay Therapeutics
YC W20San Francisco, US · Founded 2019 · 6 employees · 6 known investors
Find your way into Altay Therapeutics
11,414 people in our graph can introduce you to the Altay Therapeutics team.
Sign up to see every warm intro you have to Altay Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Altay Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
Also known as Altay Therapeutics Inc
BiotechDigital HealthHealthtechMedical DevicesAI-powered Drug DiscoveryTherapeuticsDrug discoveryUnited States of AmericaAmerica / Canada
Founders & leadership· Y Combinator alumni (W20)
Altay Therapeutics was founded in 2019 by Ali Ozes and Osman Ozes.
AO
Ali OzesFounder and CEOFounder of Altay Therapeutics, which develops small molecule inhibitors targeting transcription factors to treat facioscapulohumeral muscular dystrophy, cancer, and inflammatory conditions.
OO
Osman OzesFounder and Chief Scientific OfficerOsman Ozes has over 30 years of academic research experience and 10 years in industry, with expertise in fibrosis, cancer immunology, and inflammatory diseases. He previously directed research at Intermune, where he led biomarker discovery for Pirfenidone (Esbriet), an FDA-approved lung fibrosis treatment; as founder and Chief Scientific Officer of Altay Therapeutics, he developed a platform targeting transcription factors for drug development.
JB
JAMES BREITMEYERNamed on SEC filing
EB
ERIC BJERKHOLTNamed on SEC filing
MG
MIKE GREYNamed on SEC filing
ES
ESTER SKLARSKYNamed on SEC filing
AK
AIDAN KINGNamed on SEC filing
CJ
CHELSEA JOHNSONNamed on SEC filing
Investors · 6
Jude Gomilalisted by Jude GomilaLynnwood
How we know: Jude Gomila's portfolio page · Not right? Tell us
Y Combinatorlisted by Y CombinatorSan Francisco · $500K
How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us
Fshd Global Research FoundationreportedSydney South
How we know: Y Combinator's founder network · Not right? Tell us
Also in the syndicate · 1
SOLVE FSHD
Reported raises · per SEC filings
Form D private placements$15.7M disclosed across 1 of 2 rounds · 2022–2026
▶$15.7MraisedOct 2026 · 19 investors · BiotechnologyRule 506(b)
▶$15.7MraisedOct 2026 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES BREITMEYERExecutive Officer, Director
- ALI OZESExecutive Officer
- ERIC BJERKHOLTDirector
- MIKE GREYDirector
- ESTER SKLARSKYDirector
- AIDAN KINGDirector
- CHELSEA JOHNSONDirector
- Offering amount
- $45.1M
- Amount sold
- $15.7M
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 9
Paceline BioPlay Health builds a clinical decision-support platform for healthcare providers to deliver personalized menopause and women's health care. The platform serves primary care physicians and other providers treating women navigating perimenopause and menopause.
Ångström AIÅngström AI develops AI-powered physics simulations for pharmaceutical drug discovery, computing molecular properties like solubility, lipophilicity, and crystal structure stability to replace traditional lab experiments. The platform uses machine learning interatomic potentials and free energy calculations to accelerate and derisk solid form development for pharma companies.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Lavo Life SciencesLavo Life Sciences offers computational molecular simulations to pharmaceutical companies, helping them optimize drug formulations, reduce experimental costs, and accelerate the path to clinical trials and regulatory approval.
Numerion LabsNumerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.
Harmonic DiscoveryHarmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Coya TherapeuticsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
AlloyAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Companies working in the same space as Altay Therapeutics.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2023 | $275K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $399.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $299.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Legal entities · 1
corporate structureAltay Therapeutics, Inc.
In the news
Frequently asked questions
- What does Altay Therapeutics do?
- Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
- Who founded Altay Therapeutics?
- Altay Therapeutics was founded by Ali Ozes, Osman Ozes in 2019.
- Who are Altay Therapeutics's investors?
- Altay Therapeutics's investors include Creative Destruction Lab (CDL), Jude Gomila, Tachyon Ventures, Y Combinator, Fshd Global Research Foundation.
- How much funding has Altay Therapeutics raised?
- Altay Therapeutics has disclosed $15.7M raised across 1 of its 2 known rounds.
- Where is Altay Therapeutics headquartered?
- Altay Therapeutics is headquartered in San Francisco, US.